Objective To observe the effects of Edaravone Dexborneol combined with Tirofiban on early neurological deterioration(END)in patients with acute perforator artery infarction.Methods From October 2021 to October 2022,110 patients with acute perforator artery infarction hospitalized in the Department of Neurology of our hospital were selected.According to the random number table method,the patients were divided into control group and observation group.The control group was treated with Tirofiban injection,and on the treatment basis of control group,Edaravone Dexanetol was added in the observation group.The NIHSS score was evaluated on the first day and the third day after admission,and the incidence of END was compared between the two groups.The influencing factors of END were analyzed.Results The incidence of END in the control group was 25.45％,which was significantly higher than that in observation group(5.45％)(x2=8.419,P=0.004).Multivariate Logistic regression analysis showed that diabetes,high NIHSS score and high high-sensitivity C-reactive protein level at admission were risk factors for END in patients with perforator artery infarction,while Edaravone Dexborneol combined with Tirofiban treatment was a protective factor(all P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(x2=0.785,P=0.376).Conclusions Edaravone Dexborneol combined with Tirofiban can reduce the incidence of END events in patients with perforator artery infarction and has good safety.Inflammation may be an independent risk factor for END events in perforator artery infarction.

Objective To observe the effects of Edaravone Dexborneol combined with Tirofiban on early neurological deterioration(END)in patients with acute perforator artery infarction.Methods From October 2021 to October 2022,110 patients with acute perforator artery infarction hospitalized in the Department of Neurology of our hospital were selected.According to the random number table method,the patients were divided into control group and observation group.The control group was treated with Tirofiban injection,and on the treatment basis of control group,Edaravone Dexanetol was added in the observation group.The NIHSS score was evaluated on the first day and the third day after admission,and the incidence of END was compared between the two groups.The influencing factors of END were analyzed.Results The incidence of END in the control group was 25.45％,which was significantly higher than that in observation group(5.45％)(x2=8.419,P=0.004).Multivariate Logistic regression analysis showed that diabetes,high NIHSS score and high high-sensitivity C-reactive protein level at admission were risk factors for END in patients with perforator artery infarction,while Edaravone Dexborneol combined with Tirofiban treatment was a protective factor(all P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(x2=0.785,P=0.376).Conclusions Edaravone Dexborneol combined with Tirofiban can reduce the incidence of END events in patients with perforator artery infarction and has good safety.Inflammation may be an independent risk factor for END events in perforator artery infarction.